Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Single Dose of Merck S. Aureus Vaccine (V710) in Healthy Male Japanese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs V-710 (Primary)
- Indications Staphylococcal infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Merck Sharp & Dohme Corp.
- 25 Jun 2012 Primary endpoints amended as reported by ClinicalTrials.gov.
- 10 Nov 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Jan 2009 Planned end date (Mar 2010) added as reported by ClinicalTrials.gov.